Abstract

BackgroundCDKN2B antisense RNA 1 (CDKN2B-AS1), a long noncoding RNA, was reported to play crucial roles in the progression of multiple cancers. However, the functional roles and regulatory mechanism of CDKN2B-AS1 in human laryngeal squamous cell cancer (LSCC) remain unclear. The goals of this study were to investigate biological roles and underlying mechanisms of CDKN2B-AS1 in LSCC.MethodsThe expressions of CDKN2B-AS1, miR-497 and cyclin-dependent kinase 6 (CDK6) were detected in LSCC tissues and cell lines by real-time quantitative PCR (qRT-PCR). The effects of CDKN2B-AS1 on LSCC cell proliferation, apoptosis, migration and invasion were examined by corresponding experiments. Bioinformatics analysis and luciferase activity assay were applied to analyze the interaction between CDKN2B-AS1 and miR-497.ResultsThe expression of CDKN2B-AS1 was significantly higher in LSCC tissues than in adjacent normal tissues. Higher CDKN2B-AS1 was closely associated with lymph node metastasis and advanced clinical stage. Moreover, CDKN2B-AS1 knockdown by siRNA significantly inhibited the proliferation, induced cell apoptosis, and suppressed migration and invasion in LSCC cells. Mechanically, CDKN2B functions as an oncogenic lncRNA in LSCC via regulating miR-497/CDK6 axis.ConclusionThe observations in this study identify CDKN2B-AS1 an oncogenic role in the tumorigenesis of LSCC by regulating miR-497/CDK6 axis and indicate that it may serve as a potential target for LSCC treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.